Sculptra vs Radiesse: PLLA or CaHA Biostimulator?

Side-by-side comparison

Why the early changes differ

Sculptra is supplied as a dry PLLA-containing product that must be reconstituted before injection. The US instructions explain that early swelling, bruising and injected fluid can temporarily change the appearance; the original depression may become visible again before gradual correction develops over the following weeks. Judging the collagen response from a same-day photograph therefore confuses temporary volume with the intended longer process.

Radiesse is a semi-solid implant made of CaHA microspheres in a water-, glycerin- and carboxymethylcellulose-based carrier gel. In an undiluted structural plan, the physical material can change contour immediately, while biological changes develop later. A diluted or hyperdiluted preparation behaves differently from a structural syringe, so “one syringe of Radiesse” does not describe one universal treatment. The cited US Radiesse wrinkle instructions do not describe hyperdilution for skin-quality treatment; do not assume that preparation is on-label. Ask whether the proposed dilution and area match the exact current Thai registration and instructions.

Both can be discussed as biostimulators, but that shared label does not make their particles, carriers, injection plans or evidence equivalent.

Goal and area fit

• Sculptra may enter the discussion when the plan accepts gradual, staged change and does not rely on the first-day appearance as the result.
• Structural Radiesse may enter the discussion when immediate support or contour is part of the goal alongside a later tissue response.
• Diluted CaHA is a separate planning question. Spreading a less-structural preparation across a broader area is not the same intervention as using concentrated product for contour, and may be off-label depending on the exact product, preparation, country and indication.
• Neither product diagnoses the problem. Hollowness, loose skin, a weak bony contour, facial fat change and surface texture may need different plans — or no injectable at all.

Area claims require particular care. The current US Sculptra label covers specified facial wrinkles and folds, warns against injection into the lip vermilion and notes that periorbital injection has not been studied. The cited US Radiesse wrinkle-label covers moderate-to-severe facial wrinkles and folds, and says safety and effectiveness in the lips and periorbital area have not been established. Other Radiesse product variants have separate US indications. None of those US records establishes what is registered or indicated in Thailand.

Sessions, timing and evidence limits

There is no safe conversion such as “one Radiesse syringe equals one Sculptra vial,” and there is no fixed session count that applies across faces. Material, preparation, treatment area, degree of correction, previous injectables and response all change the plan. Sculptra is commonly assessed as a series because its visible correction develops gradually. Radiesse may be used in one session with later reassessment, but some patients and indications in its US studies received additional treatment.

The study designs should not be turned into personal schedules. The cited Sculptra cheek-wrinkle trial allowed an initial treatment and up to three additional treatments at monthly intervals. A cited Radiesse nasolabial-fold trial allowed up to three injections during its initial treatment phase. These were product- and indication-specific protocols, not proof that every person needs those numbers.

A small 21-person, 13-week study directly compared biological signals after PLLA and CaHA injections. It identified differences in gene expression, but did not test a universal cosmetic winner, session plan or duration. Six of its seven authors listed Galderma or ALASTIN affiliations, relevant because Galderma makes Sculptra; that company-linked evidence should be interpreted cautiously. Product-specific trials support selected uses in selected populations, but they do not justify a fixed promise about how long either treatment will last in every area.

Side effects, lumps and nodules

Both injections can cause swelling, redness, bruising, tenderness, pain, itching and temporary unevenness. Infection, inflammatory reactions, papules, lumps or nodules can occur. Timing matters: an early firm area with improving swelling is not automatically the same as a persistent, delayed, red, hot or painful nodule.

Sculptra's US instructions specifically describe delayed subcutaneous papules and nodules, and warn that superficial injection and overcorrection can increase local problems. The Radiesse information also reports nodules and warns that infection may be difficult enough to require attempted removal. Neither problem should be diagnosed from a photograph or treated with a generic massage or injection protocol.

The exact label also changes screening. The cited Sculptra instructions list hypersensitivity, severe allergy history and susceptibility to keloid or hypertrophic scarring among contraindications. The cited Radiesse instructions list hypersensitivity, severe allergy history and bleeding disorders. Both say safety in pregnancy or breastfeeding has not been established in their US information. The local label and a clinician's assessment control — not a comparison chart.

Vascular risk and emergency signs

Both labels warn that accidental entry into a blood vessel can cause embolization or occlusion, tissue ischemia or infarction, skin necrosis, vision impairment or blindness, and stroke. A familiar brand, a cannula, aspiration or a small volume cannot guarantee that this will not happen.

Unusual or escalating pain, skin that becomes pale, white, grey, blue or mottled, any visual change, severe headache, facial or limb weakness, speech difficulty or another sudden neurological symptom needs urgent medical assessment. Do not wait for a routine cosmetic review or try to massage the area. In Thailand, emergency medical services can be reached at 1669.

Why neither has an HA-style dissolver

Sculptra and Radiesse are not hyaluronic-acid fillers. Hyaluronidase does not dissolve PLLA particles or CaHA microspheres. Although the materials are designed to break down over time, biodegradability is not the same as having a rapid, predictable reversal injection.

Management depends on what actually happened — temporary swelling, uneven placement, a non-inflammatory nodule, inflammation, infection or vascular compromise are different diagnoses. Some complications can be difficult to treat and may require prolonged specialist care. This lack of simple reversibility deserves weight before injection, not only after a problem appears.

Authorization and product checks

“FDA approved” is incomplete unless the speaker names the country, exact product, formulation and indication. The US FDA and manufacturer documents cited here describe US labeling; they do not prove Thai registration, a Thai indication, every advertised body area or approval of another PLLA or CaHA brand.

• Ask for the exact product name, manufacturer and formulation — not only “PLLA,” “CaHA” or “collagen booster.”
• Check the Thai label, registration record, lot number, expiry date and intact packaging before treatment.
• Confirm how the product will be prepared or diluted and whether that preparation matches the registered instructions.
• Keep a photograph of the box, label and lot number in case follow-up is needed later.

Decision checklist

• What is the diagnosed issue: volume loss, structural support, skin laxity, texture or several causes?
• Why does this exact material and preparation fit that issue better than HA filler, an energy device, surgery or no treatment?
• Which areas and tissue planes are planned, and which areas will be avoided?
• What previous filler, biostimulator, permanent injectable or surgery is already in the area?
• What early change is expected, when will the response be assessed and what would count as a weak response?
• How will the clinic assess a persistent nodule, infection or possible vascular complication?

The bottom line

Sculptra and Radiesse are different particle-based injectables: reconstituted PLLA with a gradual correction pattern versus CaHA in a carrier gel that can provide earlier structural change as well as a later tissue response. That distinction can guide a consultation, but it does not select a winner. The exact goal, area, preparation, Thai registration, contraindication screening, injector judgment and lack of an HA-style dissolver matter more than a generic “best biostimulator” claim.